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Abstract
Molecular signatures are computational or mathematical models created to diagnose disease and other phenotypes and to
predict clinical outcomes and response to treatment. It is widely recognized that molecular signatures constitute one of the
most important translational and basic science developments enabled by recent high-throughput molecular assays. A
perplexing phenomenon that characterizes high-throughput data analysis is the ubiquitous multiplicity of molecular
signatures. Multiplicity is a special form of data analysis instability in which different analysis methods used on the same
data, or different samples from the same population lead to different but apparently maximally predictive signatures. This
phenomenon has far-reaching implications for biological discovery and development of next generation patient diagnostics
and personalized treatments. Currently the causes and interpretation of signature multiplicity are unknown, and several,
often contradictory, conjectures have been made to explain it. We present a formal characterization of signature multiplicity
and a new efficient algorithm that offers theoretical guarantees for extracting the set of maximally predictive and non-
redundant signatures independent of distribution. The new algorithm identifies exactly the set of optimal signatures in
controlled experiments and yields signatures with significantly better predictivity and reproducibility than previous
algorithms in human microarray gene expression datasets. Our results shed light on the causes of signature multiplicity,
provide computational tools for studying it empirically and introduce a framework for in silico bioequivalence of this
important new class of diagnostic and personalized medicine modalities.
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Introduction
A molecular signature is a computational or mathematical model
that predicts a phenotype of interest (e.g., diagnosis or outcome of
treatment in human patients or biological models of disease) from
microarray gene expression or other high-throughput assay data
inputs [1,2]. Multiplicity is a special form of data analysis instability
in which different analysis methods used on the same data, or
different samples from the same population lead to different but
apparently maximally predictive signatures [3,4]. This phenomenon has
far-reaching implications for biological discovery and development
of next generation patient diagnostics and personalized treatments.
Multiplicity in the best case implies that generation of biological
hypotheses (e.g., discovery of potential drug targets) is very hard
even when signatures are maximally predictive of the phenotype
since thousands of completely different signatures are equally
consistent with the data. In the worst case this phenomenon entails
that the produced signatures are not statistically generalizable to
new cases, and thus not reliable enough for translation to clinical
practice.
Some authors motivated by classical statistical considerations,
attribute signature multiplicity solely to the small sample size of
typical microarray gene expression studies [5] and have conjec-
tured that it leads to non-reproducible predictivity when the
signatures are applied in independent data [6]. Related to the
above it has been suggested that building reproducible signatures
requires thousands of observations [7]. Other authors have
proposed that the phenomenon of signature multiplicity is a
byproduct of the complex regulatory connectivity of the
underlying biological system leading to existence of highly
predictively redundant biomarker sets [8]. The specifics of what
types of connectivity or regulatory relationships may lead to
multiplicity have not been concretely identified however. Another
possible explanation of signature multiplicity is implicit in
previously described artifacts of data pre-processing. For example,
normalization may inflate correlations between genes, making
some of them interchangeable for prediction of the phenotype
[9–11].
Critical to the ability to study the phenomenon empirically is
the availability of computational methods capable of extracting
multiple signatures from the data. Several methods have been
introduced with this intent. The available methods encompass four
algorithm families. The first family is resampling-based signature
extraction. It operates by repeated application of a signature
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[6,12,13]. This family of methods is based on the assumption that
multiplicity is strictly a small sample phenomenon. The second
family is iterative removal, that is repeating signature extraction after
removing from the data all genes that have been found in the
previously discovered molecular signatures [14]. This approach is
agnostic as to what causes multiplicity and is heuristic since it does
not propose a theory of causes of multiplicity. The third family is
stochastic gene selection techniques [15,16]. The underlying premise of
the method of [15] is that in a specific class of distributions every
maximally predictive and non-redundant signature will be output
by a randomized algorithm with non-zero probability (thus all
such signatures will be output when the algorithm is applied an
infinite number of times). Similarly, the method of [16] will output
all signatures discoverable by a genetic algorithm when it is
allowed to evolve an infinite number of populations. The fourth
family is brute force exhaustive search [17]. This approach is agnostic as
to what causes multiplicity, and requires time that is exponential to
the total number of genes, thus it is computationally infeasible for
signatures with more than 2–3 genes (as almost all maximally
predictive signatures are in practice).
The above methods, useful first attempts as they may be, are
either heuristic or computationally intractable, are based on
currently unvalidated conjectures about what causes multiplicity,
and output incomplete sets of signatures with currently unknown
generalizability. The practical benefits of an algorithm that could
systematically extract the set of truly maximally predictive and
non-redundant signatures include: (i) a deeper understanding of
the signature multiplicity phenomenon and how it affects
reproducibility of signatures; (ii) improving discovery of the
underlying biological mechanisms by not missing genes that are
implicated mechanistically in the disease processes; and (iii)
catalyzing regulatory approval by establishing in-silico equivalence
to previously validated signatures in a manner similar to
bioequivalence of drugs.
To achieve these goals we provide a theoretical framework
based on Markov boundary induction that enables probabilistic
modeling of multiple signatures and formally connects it with
the causal graph (i.e., pathways) of the data generating process
[18–21] even when these pathways are not known a priori. We
introduce a provably correct algorithm (termed TIE*) that outputs
the set of maximally predictive and non-redundant signatures
independent of the data distribution. We present experiments with
real and resimulated microarray gene expression datasets as well
as with artificial simulated data that verify the theoretical
properties of TIE* and showcase its advantages over previous
methods in practical settings. In particular, it is shown that TIE*
having excellent sample and computational efficiency not only
extracts many more maximally predictive and non-redundant
signatures than all previous methods, but also that TIE* signatures
are reproducible in independent datasets whereas signatures
produced by previous methods are often not reproducible or have
lower predictivity. The theoretical and experimental results
obtained in the present study also suggest that some of the
previous hypotheses about the causes and implications of signature
multiplicity have to be radically reevaluated.
Materials and Methods
On analysis of signatures
To simplify analysis, and without loss of generality, instead of
considering all possible signatures derivable from a given dataset
(via a potentially infinite variety of classifier algorithms) we only
consider the signatures that have maximal predictivity for the
phenotypic response variable relative to the genes (variables) contained in
each signature. In other words, we exclude from consideration
signatures that do not utilize all predictive information about the
phenotypic response variable contained in their genes. This allows
us to study signature classes by reference only to the genes
contained in each class. Specifically, for a gene set X there can be
an infinite number of classifiers that achieve maximal predictivity
for the phenotype relative to the information contained in X.
Thus, when we say ‘‘signature X’’ we refer to one of these
predictively equivalent classifiers. This reduction is justified, for
example, whenever the classifiers used can learn the minimum
error decision function given sufficient sample (for a given set of
genes X, the minimal error decision function minimizes the error
of predicting the phenotypic variable T given X over all possible
decision functions). Most practical classifiers employed in this
domain as well as classifiers used in our experiments (SVMs) satisfy
the above requirement either on theoretical [22,23] and/or
empirical grounds [24].
Given the above reduction of signatures to equivalence classes,
the focus of this work is in extracting signatures that satisfy two
desirable optimality properties: (a) maximally predictive of the phenotype
(informally this means that they can form the inputs to a predictor
of the phenotype which for the given dataset and population
cannot be improved by any other classifier-gene subset combina-
tion), and at the same time (b) do not contain predictively redundant genes
(i.e., genes that can be removed from the signature without
adversely affecting the signature predictivity). Every suboptimal
signature (i.e., one that does not satisfy these two properties) can be
discarded from consideration when studying multiplicity.
Markov boundary characterization of signature
multiplicity
As is proved in Text S1, two signatures X and Y of the
phenotypic response variable T are maximally predictive and non-
redundant if and only if X and Y are Markov boundaries of T.A
Markov boundary M of T is a set of variables that (i) renders all
other variables outside M and T independent of T conditioned on
M (i.e., M is a Markov blanket of T) and (ii) no proper subset of M
is a Markov blanket of T [18]. This definition also implies causal
interpretability of M under distributional assumptions [18–21]. It
was shown previously that the so-called intersection property of
Author Summary
One of the promises of personalized medicine is to use
molecular information to better diagnose, manage, and
treat disease. This promise is enabled through the use of
molecular signatures that are computational models to
predict a phenotype of interest from high-throughput
assay data. Many molecular signatures have been devel-
oped to date, and some passed regulatory approval and
are currently used in clinical practice. However, researchers
have noted that it is possible to develop many different
and equivalently accurate molecular signatures for the
same phenotype and population. This phenomenon of
signature multiplicity has far-reaching implications for
biological discovery and development of next generation
patient diagnostics and personalized treatments. Currently
the causes and interpretation of signature multiplicity are
unknown, and several, often contradictory, conjectures
have been made to explain it. Our results shed light on the
causes of signature multiplicity and provide a method for
extracting all equivalently accurate signatures from high-
throughput data.
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Markov boundaries [18], therefore it is also a sufficient condition
for uniqueness of optimal molecular signatures. However, the
extent to which signature multiplicity is present in distributions
that violate the intersection property is not known.
Figure 1 shows by means of an illustrative example implications
of signature multiplicity. It describes a class of Bayesian networks
that share the same pathway structure (with three gene variables A,
B, C and a phenotypic response variable T) and constraints on
their joint probability distributions. Each member of this class is
derived by parameterizing the joint probability distribution subject
to the constraints. An example of a parameterized Bayesian
network is provided in Figure S1. The following hold in all
Bayesian networks that belong to this example class:
N There exist two maximally predictive and non-redundant
signatures (Markov boundaries) of T:{ A, C} and {B, C}.
Furthermore, {A, C} and {B, C} remain maximally predictive
and non-redundant signatures even in infinite samples from
that distribution (i.e., multiplicity does not vanish in the large sample).
N The pathway structure has very low connectivity (e.g.,
maximum in-degree =1 and maximum out-degree =2) (i.e.,
multiplicity does not require very dense connectivity).
N A and B are not deterministically related, yet they convey
individually the same information about T (i.e., multiplicity does
not require deterministic equivalence or extreme collinearity).
N If an algorithm selects only one maximally predictive and non-
redundant signature (e.g., {B, C}), then there is danger of
missing biologically important (causative) genes (i.e., A) and
focusing instead on confounded genes (i.e., B) (i.e., only some of
the predictively equivalent signatures have local causal interpretation).
N The union of all maximally predictive and non-redundant
signatures includes all genes located in the local pathway
around T, i.e., A and C (we define local pathway as genes directly
upstream or downstream of the response variable T.).
N In this example, the intersection of all maximally predictive
and non-redundant signatures contains only genes in the local
pathway around T (i.e., C).
The above example is concerned with the large sample case. In
practice, one deals with small samples where statistical inferences
have to be made about large sample predictivity and redundancy.
This creates an additional source of error and concomitant
multiplicity. An example of this is given in Text S2.
TIE* algorithm for identification of the set of maximally
predictive and non-redundant signatures
Figure 2 presents the high-level operation of the TIE* algorithm
that uses Markov boundary induction to identify the set of
maximally predictive and non-redundant signatures. Text S3
provides an example trace, proof of correctness, and implemen-
tation details of the algorithm. In step 1, TIE* uses a base Markov
boundary induction algorithm that identifies a single molecular
signature M of the phenotype with maximal predictivity and no
redundancy (Markov boundary). The same base algorithm is
applied repeatedly to versions of the original dataset in which some
subset of variables G has been removed (step 4). If a new signature
Mnew has the same predictivity for the phenotype as M, then it is a
Markov boundary and it is output (step 5). Steps 3–5 are repeated
until no subset G can be generated in step 3.
The base Markov boundary induction algorithm must be
suitable for the distribution at hand. Thus, TIE* is a generative
Figure 1. The figure describes a class of Bayesian networks that share the same pathway structure (with 3 gene variables A, B, C and
a phenotypic response variable T) and their joint probability distribution obeys the constraints shown below the structure. Red
dashed arrows denote nonzero conditional probabilities of each variable given its direct causes, and the absence of red dashed arrows denotes that
these conditional probabilities are zero. For example, P(T=0|A=1)?0 while P(T=0|A=2) =0. Genes A, B and phenotypic response variable T take 3
values {0, 1, 2}, while gene C takes two values {0, 1}.
doi:10.1371/journal.pcbi.1000790.g001
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In the experiments reported in this paper, we use as the base
algorithm HITON-PC (Figure S2), which is an instance of a very
broad class of Markov boundary inducers termed Generalized Local
Learning [25,26]. This choice of the base algorithm is motivated by
its empirical performance in microarray gene expression and other
high-throughput data as well as its theoretical properties [25–28].
TIE* is guaranteed to be correct in the large sample under its
stated assumptions. In the small sample some signatures that are
not maximally predictive and/or redundant will be statistically
indistinguishable from the maximally predictive and non-redun-
dant ones. This indistinguishability occurs at two different levels:
one is estimation of predictivity and testing for statistical
significance of differences in predictivity among signatures. The
second level is the performance of tests of conditional indepen-
dence (or functional equivalents such as Bayesian scoring) with
small samples inside the base algorithm which incurs errors of type
I and II. As the sample size grows, the algorithm will output only
truly maximally predictive and non-redundant signatures.
We present several experiments testing the new algorithm and
comparing it against 8 previously described multiple signature
extraction methods. The methods comprise of four resampling-
based algorithms, one iterative removal method, and three
stochastic gene selection methods (details in Text S4). Brute force
exhaustive search and genetic algorithms were not applied due to
their computational intractability.
Before applying TIE* to real data, we test its behavior in
controlled (i.e., simulated and resimulated data) experiments
where generative models are known and in the case of simulated
data all maximally predictive and non-redundant signatures are
known as well (details about data generation are provided in Text
S5). This allows us to test whether the algorithm behaves
according to theoretical expectations, whether it is robust to
moderate sample sizes, and whether it is sensitive to high
dimensionality. This also provides clues about the behavior of
TIE* and the baseline comparison algorithms in our experiments
with real human microarray data.
Reproducibility testing protocol, human microarray gene
expression datasets, and empirical criterion for assessing
maximal predictivity of signatures
To test reproducibility of molecular signatures, we adopt an
experimental design where one microarray dataset (‘‘discovery
dataset’’) is used for identification of signatures and estimation of
their predictivity by holdout validation [29], and another
independent dataset (‘‘validation dataset’’) originating either from a
different laboratory or from a different microarray platform is used for
validation of predictivity of the signatures. No overlap of subjects
between discovery and validation dataset analyses occurs in this
design. The criteria for dataset admissibility and exact protocol for
quality assurance and processing of pairs of datasets is described in
Text S6. In total, 6 pairs of gene expression microarray datasets
covering both human cancer diagnosis and outcome prediction
were used (listed in Table S1).
Operationally we define maximal predictivity for each dataset as
follows: we apply all tested methods for extraction of multiple
signatures to a dataset; then for each method we compute average
predictivity of the phenotype (over all identified signatures by this
method) measured by area under ROC curve (AUC); finally we
compute the maximum value of the above average predictivity
estimates and refer to it as ‘‘maximal predictivity’’.
Statistical comparisons of predictivity between methods in the
same dataset are accomplished by Wilcoxon rank sum test with
a=0.05 [30]. This is a two-sided test of the null hypothesis that
two samples come from distributions with equal medians. When
we use this test, the first sample contains AUC estimates of all
Figure 2. High-level pseudocode of the TIE* algorithm. Non-redundancy is not explicitly checked during the operation of TIE* but is a required
property of the base Markov boundary algorithm. Details are provided in Text S3.
doi:10.1371/journal.pcbi.1000790.g002
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and the second sample contains AUC estimates of all signatures
identified by another method.
Results
Experiments with artificial simulated data
Tables S2 and S3 present the results of experiments with TIE*
and baseline comparison algorithms. The following are observed:
(i) TIE* perfectly identifies all 72 maximally predictive and non-
redundant signatures that exist in the distribution using datasets
with either 30 or 1,000 variables; (ii) iterative removal identifies
only 1 signature because all other signatures have a common
variable and thus cannot be detected by this method; (iii) KIAMB
fails to identify any optimal signature due to its sample inefficiency,
and because of the same reason its signatures have poor
classification performance; (iv) resampling-based methods either
miss many optimal signatures and/or output many redundant
variables in the signatures.
Experiments with resimulated gene expression
microarray data
We applied TIE* to resimulated gene expression data with
sample sizes: 300, 450,…, 1500, 2250, 3000,…, 30000. A
signature is operationally considered as non-reducible if it is not
properly included in any other signature output by this method
(i.e., it is a proxy of having no redundant genes). For example, if a
method outputs 3 signatures with the following genes: {A, B, C},
{A, B, X}, and {A, B}, only signature {A, B} is non-reducible. The
number of maximally predictive signatures (as confirmed in
independent data by holdout validation) and the number of
maximally predictive and non-reducible signatures output by the
algorithm for each sample size in resimulated data is shown in
Figure S3. As sample size increases, the number of output
maximally predictive signatures drops but then remains constant
in the range 160–644 (or 53–279 for non-reducible signatures) for
datasets with $4,500 samples. This is consistent with the existence of at
least two sources of multiplicity: one is small sample size and the other
is multiplicity intrinsic to the nature of gene-gene and gene-
phenotype relations. As sample size grows, the first source vanishes
and only the second one remains. Since the resimulated data
distribution closely mimics the real-life distribution (Text S5), this
experiment supports the hypothesized existence of multiple
maximally predictive and non-redundant signatures in very large
samples (.10,000) contrary to the theoretical model of [5].
Experiments with real human data showing that
signatures produced by TIE* have maximal predictivity in
independent validation datasets
Table S4 shows that TIE* achieves maximal predictivity in 5
out of 6 human microarray validation datasets. Non-TIE*
methods achieve maximal predictivity in 0 to 2 datasets depending
on the method. In the dataset where TIE* has predictivity that is
statistically distinguishable from the empirical maximal one (Lung
Cancer Subtype Classification), the magnitude of this difference is
,0.009 AUC on average over all discovered signatures; thus this
particular deviation from maximal predictivity may be considered
negligible for most practical purposes.
A detailed example of application of multiple signature extraction
methods to the Leukemia 5 Yr. Prognosis task is provided in Figure 3.
The figure shows predictivity estimated in the discovery dataset
(using an unbiased error estimator and protocol) against predictivity
verified in the validation dataset for each signature. As can be seen,
TIE* signatures have superior predictivity and lower variance
compared to the signatures output by other methods. Similar
behavior can be observed in other tasks as well.
Experiments with real human data showing that
signatures produced by TIE* are statistically reproducible
whereas signatures from other methods are often
overfitted
Figure 4 plots predictivity estimated in the discovery dataset
(using an unbiased error estimator and protocol) against pre-
dictivity verified in the validation dataset for all methods averaged
over all datasets and all discovered signatures. Recall that validation
datasets originate from different laboratories and/or using different
microarray platforms than discovery datasets. The horizontal
distance of each method to the diagonal measures the magnitude
of overfitting defined as the difference (e1-e2), where e1 = expected
performance in the validation data obtained by holdout validation
in the discovery dataset, and e2 = observed validation dataset
performance. TIE* rests slightly right of the diagonal denoting no
overfitting, or equivalently perfect statistical reproducibility on
average. However all other methods exhibit varying degrees of
non-reproducibility. Depending on method the average magnitude
of overfitting varies from 0.02 to 0.03 AUC.
Signatures produced by TIE* in human microarray data
have many genes in common
Analysis of the signatures output by TIE* reveals that they share
many genes in common. Table S5 shows the number of common
genes in 50%, 60%, …, 100% of output signatures for each
dataset. Genes differ in the percentage of signatures they
participate in. A heuristic that genes that belong to a larger
fraction of signatures are localized closer to the pathway(s)
affecting and being affected by the phenotypic response variable
may be useful in exploratory studies, however this does not hold in
all distributions [31].
Discussion
Computational complexity of the multiple signature
discovery problem
The properties of the data-generative process affect computa-
tional feasibility of the signature discovery. In the worst case, it is
computationally infeasible to discover even one of all optimal
signatures with all known sound algorithms (i.e., algorithms that
under specific conditions provably guarantee to provide the
desired output; for the purposes of the present paper, to find a
signature that is optimal in the population). However, there exist
several sound algorithms for extracting an optimal signature that
run in low-order polynomial time in real high-throughput data
(e.g., HITON-PC). Even if the computational cost of discovery of
one signature was constant, the number of all optimal signatures
can grow exponentially large in the number of genes measured (for
an example see Text S7). Thus the computational cost of
dissecting signature multiplicity ranges from low-order polynomial
(tractable) to super-exponential (infeasible) depending on the
distribution. The worst-case characteristics are a property of the
distribution analyzed and not the algorithm employed. One can
thus only hope that real-life high-throughput data distributions are
not representative of the worst-case theoretical ones. In addition,
algorithms are needed that exploit the structure of the generative
process to discover multiple signatures efficiently when the
distribution allows it. Our experiments support that real-life data
does not behave as the worst-case expected theoretical scenarios
Understanding Signature Multiplicity
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the 6 microarray datasets that contains more than 10,000
oligonucleotide probes (using a Matlab implementation on a
workstation with a single Intel Xeon 2.4 GHz processor and 4Gb
of RAM). One can postulate various reasons for the tractability
such as: (a) that biological pathways are sufficiently sparse thus not
allowing for an exponential number of optimal signatures; (b) that
to the extent that multiplicity denotes biologically redundant
function, there is an ‘‘economy’’ of such redundant mechanisms,
and (c) that a very large number of optimal signatures requires
constraints on the network topology that are inconsistent with the
structure of many biologically functional pathways.
Understanding causes of signature multiplicity
The results of the present study refute or suggest that
modifications are needed to several widespread positions about
causes of signature multiplicity. The example model pathway in
Figure 1 demonstrates that signature reproducibility neither
precludes multiplicity nor requires sample sizes with thousands of
subjects. It also shows that multiplicityof signatures does not require
dense connectivity of the underlying pathways. Similarly, it shows
that noisy measurements or normalization are not necessary
conditions for signature multiplicity. The resimulation experimental
data suggest that networks modeled on real gene expression data
can exhibit signature multiplicity even in large sample sizes and that
in this type of data, multiplicity is produced by a combination of
small sample size-related variance and intrinsic multiplicity in the
underlying network. The results with real human microarray
datasets show that multiple signatures output by TIE* are
reproducible and maximally predictive even though they are
derived from small sample, noisy, and heavily-processed data.
Our results are consistent with the hypothesis that signature
multiplicity in real-life datasets is created by a combination of
several factors that include the following: First, the intrinsic
information redundancy (due to gene-gene and gene-phenotype
relations) in the complex regulatory network of the underlying
biological system. Second, the variability in the output of gene
selection and classifier algorithms especially in small sample sizes.
Third, the small sample statistical indistinguishability of signatures
that have different large sample predictivity and/or redundancy
characteristics (example is given in Text S2). Fourth, the presence of
hidden/unobserved variables (example is given in Text S8). Fifth,
correlated measurement noise components that introduce a bias in
gene expression profiles (e.g., noise that is localized in regions of
microarray chips) [32]. Sixth, RNA amplification techniques that
systematically distort measurements of transcript ratios (e.g.,
Figure 3. Plot of classification performance (AUC) in the validation dataset versus classification performance in the discovery
dataset for each signature output by each method for the Leukemia 5 yr. Prognosis task. Each dot in the graph corresponds to a signature
(SVM computational model of the phenotype).
doi:10.1371/journal.pcbi.1000790.g003
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cellular aggregation and sampling from mixtures of distributions
that affect inference of conditional independence relations that are
needed to establish model equivalence according to our framework
for multiplicity [34]. Eighth, normalization and other data pre-
processing methods that artificially increase correlations among
genes (e.g., multivariate normalization in microarrays) [9–11].
Finally ninth, the engineered redundancy in the assay technology
platforms (e.g., multiple probes for the same gene). In datasets
produced by dissimilar underlying biological mechanisms, assayed
with different platforms and pre-processed and modeled with a
variety of algorithms, the relative contributions of the above
factors to multiplicity will vary. As a result, methods that rely on a
specific cause of multiplicity or combination of causes will not
output all maximally predictive and non-redundant signatures in
all types of high-throughput data.
Analysis of methods for multiple signature extraction
With regard to non-TIE* baseline comparison algorithms, we
note that resampling-based methods that use bootstrap samples to
extract signatures may stop producing multiple signatures in large
sample sizes. This is expected because resampling methods are
designed to address directly only the small sample multiplicity and
not the intrinsic multiplicity which persists in large samples.
Iterative removal, on the other hand, by its design always fails to
identify all maximally predictive and non-redundant signatures
that have genes in common. KIAMB among the baseline
algorithms has the strongest theoretical motivation because it
can be shown to discover all Markov boundaries for a subset of
distributions. However, a major limitation of KIAMB is that it has
sample size requirements that range from at least linear to
exponential to the number of genes in a signature (depending on
the test of independence employed). This makes the algorithm not
only computationally inefficient but also prone to statistical errors
in small sample sizes. This leads to its substantial observed
overfitting in the experiments with real data and its inability to find
the maximally predictive and non-redundant signatures in
simulated data. KIAMB, being a randomized search algorithm,
also guarantees to output all optimal signatures that satisfy its
distributional requirements, but only after infinite number of runs.
Figure 4. Plot of classification performance (AUC) in the validation dataset versus classification performance in the discovery
dataset averaged over 6 pairs of datasets. Axes are magnified for better visualization.
doi:10.1371/journal.pcbi.1000790.g004
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over again further compounding its computational inefficiency.
Dealing with molecular signature multiplicity using a Markov
boundary framework and the TIE* algorithm does not require a
particular combination of factors causing signature multiplicity in
order to be able to discover all maximally predictive and non-
redundant signatures. Because of efficient heuristics, TIE* can
extract the signature set very quickly when the connectivity is
locally sparse, and the number of true optimal signatures is low-
order polynomial or smaller in the number of variables. A very
important factor for the performance of TIE* is the choice of the
base algorithm to discover non-redundant and maximally
predictive signatures in the distribution at hand. Latest develop-
ments in Markov boundary discovery provide such tools for high-
throughput data. One of the key advantages of these methods is
their ability to implicitly control for false discovery rate [25].
Future research
Our experiments used real data exclusively from human cancer
gene expression microarrays because of pragmatic reasons: known
identity of observed variables, number and size of datasets, and
maturity of standardization protocols that allows for multiple
independent dataset validation experiments. The methods intro-
duced here are however directly applicable to any high-
throughput data, and future research in this direction is warranted.
As an example of applicability of TIE* to high-throughput data
beyond gene expression microarrays, we applied the method to
proteomics mass-spectrometry data where TIE* identified hun-
dreds of signatures of ovarian cancer with AUC=0.9520.98
(details in Text S9).
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